410 Medical Secures $12 Million in Growth Financing to Accelerate Commercial Expansion

410 Medical, Inc., a medical device company specializing in innovative technologies for emergency and critical care, has successfully completed a $12 million financing round. The round was led by Orlando Health Ventures, with participation from several notable investors including Hatteras Venture Partners, Ballad Health, OSF Healthcare, Rex Health Ventures, CU Healthcare Innovations Fund, Sarnova, Catalyst by Wellstar, Tampa General, and an undisclosed strategic investor. This funding round, announced on July 14, 2026, will be utilized to scale the company’s commercial operations and support the launch of its next-generation LifeFlow infuser.

410 Medical’s flagship product, LifeFlow, is designed to facilitate rapid fluid and blood delivery for patients suffering from critical conditions such as sepsis and hemorrhagic shock. The device has already been adopted by over 500 hospitals and emergency medical services (EMS) agencies across the United States, with nearly 80,000 patients treated using the technology. The recent financing aims to enhance the adoption of LifeFlow, enabling the company to penetrate new hospital systems and EMS agencies nationwide, thereby improving patient outcomes in critical care settings.

The strategic rationale behind this funding round is underscored by the growing recognition of the importance of effective resuscitation technologies in emergency medicine. The involvement of multiple healthcare investors reflects a strong belief in 410 Medical’s mission and the potential impact of its products. The leadership at Orlando Health Ventures expressed confidence in LifeFlow's ability to address significant gaps in resuscitative care, highlighting the technology's critical role in improving clinical outcomes for patients in life-threatening situations.

In addition to expanding its commercial reach, 410 Medical is also investing in the development of the next-generation LifeFlow device, which is anticipated to launch in 2027. This new iteration will incorporate feedback from nearly a decade of collaboration with frontline medical providers, focusing on enhancing speed, portability, and ease of use—key factors in emergency care. By addressing these unmet needs, 410 Medical aims to solidify its position as a leader in advanced resuscitation technologies.

The successful completion of this financing round not only signifies a strong vote of confidence from investors but also reflects broader trends in the healthcare sector, where there is an increasing emphasis on innovative medical technologies that enhance patient care. As healthcare providers continue to seek solutions that improve efficiency and outcomes in critical situations, companies like 410 Medical are well-positioned to capitalize on these dynamics. The funding will enable 410 Medical to further its mission of delivering effective resuscitation solutions, ultimately contributing to better healthcare delivery in emergency and critical care environments.